Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.35 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.35 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.35 |
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.35 |
| ▸ | P2RY4 known ✓ | P51582 | 2/20 | 0.34 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532393 | 1.00 | NR4A1 (0.51) | NR4A1AURKAAURKBFTOTTR | |
| SCHEMBL7497022 | 0.88 | NR4A1 (0.42) | NR4A1CA12CA1CA2CA4 | |
| SCHEMBL7497695 | 0.83 | NR4A1 (0.38) | NR4A1FTO | |
| SCHEMBL29516471 | 0.81 | NR4A1 (0.69) | NR4A1AURKAAURKBTTRCA12 | |
| SCHEMBL11429445 | 0.81 | NR4A1 (0.69) | NR4A1AURKAAURKBTTRCA12 | |
| SCHEMBL6615470 | 0.81 | AURKA (0.54) | NR4A1AURKAAURKBTTRCA12 | |
| SCHEMBL9746845 | 0.75 | AURKA (0.50) | NR4A1AURKAAURKBFTOTTR | |
| SCHEMBL9404215 | 0.74 | ALDH1A1 (0.48) | AURKAAURKBCYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL29583348 | 0.74 | ALDH1A1 (0.48) | AURKAAURKBCYP2C9ALDH1A1CYP3A4 | |
| SCHEMBL31134771 | 0.74 | DUSP5 (0.50) | NR4A1TTRCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116457339-A | Tricyclic compounds degrading novel substrates for medical treatment | C4医药公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-0906313-B1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-1028962-B1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6399597-B1 | CARBAPENICILLIN ANTIBIOTICS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1028962-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1032384-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1027353-A4 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1027353-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2000-08-16 | — | — | EP | disclosed |
| US-5994343-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5994345-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1999-11-30 | — | — | US | disclosed |
| CN-1222912-A | Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| WO-1999020270-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020628-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999018107-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0906313-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5756725-A | CARBAPENEM NUCLEUS IS SUBSTITUTED AT THE 2-POSITION WITH A NAPHTHOSULTAM LINKED THROUGH A CH2 GROUP | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997040048-A1 | CARBAPENEM ANTIBACTERIAL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | CRBN, CDR2, MDM2 | CA12 2657/4885CA1 2457/4885CA2 3907/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CA12 1095/4885CA1 1094/4885CA2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.